| Identification | More | [Name]
6,7,4'-Trihydroxyisoflavone | [CAS]
17817-31-1 | [Synonyms]
4',6,7-TRIHYDROXYISOFLAVONE
6,7,4'-TRIHYDROXYISOFLAVONE
DEMETHYLTEXASIN
TRIHYDROXYISOFLAVONE, 4',6,7-
TRIHYDROXYISOFLAVONE, 4',6,7-(RG)
6,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one | [Molecular Formula]
C15H10O5 | [MDL Number]
MFCD00016953 | [Molecular Weight]
270.24 | [MOL File]
17817-31-1.mol |
| Chemical Properties | Back Directory | [Melting point ]
>280℃ | [Boiling point ]
587.1±50.0 °C(Predicted) | [density ]
1.548±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
soluble in Dimethylformamide | [form ]
powder to crystal | [pka]
6.85±0.20(Predicted) | [color ]
Light yellow to Brown to Dark green | [biological source]
synthetic | [Major Application]
clinical research
general analytical
life science and biopharma
metabolomics | [InChI]
InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-14-6-13(18)12(17)5-10(14)15(11)19/h1-7,16-18H | [InChIKey]
GYLUFQJZYAJQDI-UHFFFAOYSA-N | [SMILES]
C1=CC(=CC=C1C2=COC3=CC(=C(C=C3C2=O)O)O)O | [LogP]
2.170 (est) | [CAS DataBase Reference]
17817-31-1(CAS DataBase Reference) |
| Safety Data | Back Directory | [Safety Statements ]
S22:Do not breathe dust .
S24/25:Avoid contact with skin and eyes . | [WGK Germany ]
3
| [F ]
10 | [HS Code ]
2914.69.9000 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral
Eye Irrit. 2
Skin Irrit. 2 |
| Hazard Information | Back Directory | [Uses]
4'',?6,?7-?Trihydroxyisoflavone is an isoflavone modulator of adenosine-monophosphate-activated protein kinase. | [Definition]
ChEBI: A hydroxyisoflavone that is daidzein bearing an additional hydroxy substituent at position 6. | [in vivo]
Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system[1]. | Animal Model: | Female athymic nude mice subcutaneously injected with HCT-116 cells[1] | | Dosage: | 5 or 25 mg/kg | | Administration: | Intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days | | Result: | Decreased tumor growth, volume and weight of HCT-116 xenografts. |
| [IC 50]
CDK1; CDK2; PKC |
|
|